secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2022-05-16T23:59:59+00:00
Accession:  0001140361-22-019249
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galectin Therapeutics Q1 net loss $9.9M ($0.17/shr); cash runway through May 2023
--------------------------------------------------------------------------------

- Net loss of $9.9M for Q1 2022 vs $6.3M in Q1 2021; R&D spend rose to $8.1M (up from $4.9M) on NAVIGATE trial costs.
- Cash and equivalents $31.6M; company expects to fund operations through at least May 16, 2023.
- Expects to require additional $40-45M to reach planned interim analysis of NAVIGATE trial in mid-2024.
- Phase 2b/3 NAVIGATE trial enrollment for NASH cirrhosis on track to finish Phase 2b portion around Q3 2022.
- Company preparing IND to study belapectin in combination with Keytruda for recurrent head and neck cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036122019249/0001140361-22-019249-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036122019249/brhc10037527_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-019249

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer